Amikacin therapy for severe Gram negative sepsis. Emphasis on infections with gentamicin resistant organisms

F. P. Tally, T. J. Louie, W. M. Weinstein, J. G. Bartlett, S. L. Gorbach

Research output: Contribution to journalArticle

Abstract

Amikacin (BB K8) is a semisynthetic derivative of kanamycin which is active in vitro against many gentamicin resistant Gram negative bacilli. Twenty three patients with 25 serious Gram negative infections were treated with this new aminoglycoside. Twelve infections involved organisms that were resistant to gentamicin. Twenty patients satisfied the criteria for bacteriological and clinical cure. This included 11 of the 12 infections involving gentamicin resistant Gram negative bacilli. In 4 urinary tract infections there was a good clinical response, but routine follow up urine cultures at 30 days were positive. One patient failed on amikacin therapy. Eighth nerve toxicity was detected in two patients. These results indicate that amikacin is effective in the treatment of serious Gram negative infections and is particularly useful in those involving resistant organisms. Further studies are indicated to evaluate ototoxic potential.

Original languageEnglish (US)
Pages (from-to)484-488
Number of pages5
JournalUnknown Journal
Volume83
Issue number4
DOIs
StatePublished - Jan 1 1975
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Amikacin therapy for severe Gram negative sepsis. Emphasis on infections with gentamicin resistant organisms'. Together they form a unique fingerprint.

  • Cite this